Eli Lilly will significantly increase the price of its weight-loss drug Mounjaro in the United Kingdom in a bid to bring down prices in the United States after weeks of pressure from the Trump administration.

The pricing of weight-loss and diabetes drugs like Lilly’s Zepbound and Mounjaro, and Novo’s Wegovy and Ozempic, is a pressure point for investors. Price erosion is a major worry amid increasing competition— including from knockoff versions of the drugs provided by telehealth pharmacies and coming patent expirations.

In the current market session, Eli Lilly Inc. LLY +1.10% Get Free Report price is at $702.03, after a 2.57% spike. However, over the past month, the stock fell by 9.13%, and in the past year, by 23.93%. Shareholders might be interested in knowing whether the stock is undervalued, even if the company is performing up to par in the current session.